Want to see AU:S66 full AI Analyst Report?
Top Page
Star Combo Pharma Ltd.
(Sydney:S66)
Select Model
Select Model
Rating:66Neutral
Price Target:
AU$0.15
▼(-41.60% Downside)
Action:Reiterated
Date:06/11/26
The score is supported by improved 2025 financial performance (profitability rebound, strong free cash flow, and low leverage) and attractive valuation (low P/E with a dividend). It is held back by weak technicals, with the share price below all major moving averages and negative MACD, plus a key fundamental risk that the recovery may be inconsistent given multi-year volatility and a 2025 revenue decline.
Positive Factors
Free Cash Flow Strength
Reported 2025 free cash flow of roughly $11.5M and near 1:1 conversion with net income demonstrates strong internal cash generation capacity. Durable FCF supports operations, dividends or debt reduction and provides management optionality for capital allocation over the next 2–6 months.
Negative Factors
Revenue Decline
Top-line fell about 6.3% in 2025 and recent multi-year revenue growth metrics are negative, indicating demand or share pressures. Reliance on margin gains rather than consistent volume growth makes earnings recovery vulnerable if revenue weakness persists across the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Strength
Reported 2025 free cash flow of roughly $11.5M and near 1:1 conversion with net income demonstrates strong internal cash generation capacity. Durable FCF supports operations, dividends or debt reduction and provides management optionality for capital allocation over the next 2–6 months.
Read all positive factors
Star Combo Pharma Ltd. (S66) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$18.23M
Dividend Yield1.54%
Average Volume (3M)6.77K
Price to Earnings (P/E)4.3
Beta (1Y)-0.79
Revenue Growth-18.76%
EPS Growth504.55%
CountryAU
Employees30
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.03
Shares Outstanding135,002,980
10 Day Avg. Volume4,300
30 Day Avg. Volume6,768
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.63
Price to Sales (P/S)0.86
P/FCF Ratio2.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Star Combo Pharma Ltd. Business Overview & Revenue Model
Company Description
Star Combo Pharma Limited is involved in the production and supply of health foods and dietary supplements across Australia and China. The company's activities are organized into two primary divisions: Star Combo and Austoyou Retail. It manages th...
Star Combo Pharma Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.84M | 27.81M | 26.02M | 24.70M | 22.88M | 26.72M |
| Gross Profit | 5.42M | 6.27M | 5.44M | 4.66M | 5.61M | 4.61M |
| EBITDA | 6.69M | 6.64M | 2.79M | -2.53M | -126.71K | -6.40M |
| Net Income | 5.39M | 5.25M | 747.33K | -4.00M | -696.35K | -7.88M |
Balance Sheet | ||||||
| Total Assets | 46.99M | 48.45M | 42.82M | 42.23M | 43.44M | 43.32M |
| Cash, Cash Equivalents and Short-Term Investments | 18.18M | 18.11M | 7.36M | 9.49M | 10.39M | 17.32M |
| Total Debt | 8.29M | 3.93M | 4.03M | 4.19M | 4.12M | 3.30M |
| Total Liabilities | 8.30M | 10.19M | 9.30M | 8.97M | 8.04M | 7.13M |
| Stockholders Equity | 38.54M | 38.08M | 33.32M | 33.09M | 35.41M | 36.19M |
Cash Flow | ||||||
| Free Cash Flow | 254.05K | 11.55M | -1.76M | -851.83K | -7.21M | -6.93M |
| Operating Cash Flow | 602.90K | 11.94M | -316.45K | 1.88M | 87.11K | 331.53K |
| Investing Cash Flow | -1.26M | -9.72M | -136.79K | -3.23M | -3.24M | -7.53M |
| Financing Cash Flow | -626.09K | -795.12K | -370.93K | -53.44K | -169.08K | -2.08M |
Star Combo Pharma Ltd. Technical Analysis
Negative
0.25
Price Trends
0.18
Negative
0.19
Negative
0.21
Negative
Market Momentum
-0.01
Negative
44.28
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:S66, the sentiment is Negative. The current price of 0.25 is above the 20-day moving average (MA) of 0.14, above the 50-day MA of 0.18, and above the 200-day MA of 0.21, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 44.28 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:S66.
Star Combo Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | AU$18.23M | 4.34 | 14.06% | 1.54% | -18.76% | 504.55% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | AU$108.60M | -6.03 | -164.12% | ― | -14.85% | -41.04% | |
45 Neutral | AU$18.85M | -1.36 | 2542.90% | ― | -47.12% | -18.92% | |
41 Neutral | AU$21.12M | -5.64 | -108.90% | ― | -7.01% | 26.92% | |
39 Underperform | AU$20.04M | -6.49 | -1964.93% | ― | -100.00% | 2.53% |
* Consumer Defensive Sector Average
AU:S66
Star Combo Pharma Ltd.
0.14
-0.01
-10.00%
AU:ZNO
Zoono Group Limited
0.05
0.02
70.97%
AU:NC6
Nanollose Ltd.
0.05
-0.02
-26.47%
AU:SKN
Skin Elements Limited
―
―
―
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.11
0.08
266.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.